Not finding it? Sign in to also search OpenAlex live.
-
Cardiovascular Risk Prediction Modelling with Semaglutide in Patients with Type 1 Diabetes2025 Journal of the American Society of Nephrology article Medicine Diabetes Management and Research
Massimo Nardone, Melissa‐Rosina Pasqua, Michael A. Tsoukas, Luxcia Kugathasan, Vikas S. Sridhar, Marcel H.A. Muskiet, +2 more
1citations -
Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice2023 International Journal of Molecular Sciences article Medicine Liver Disease Diagnosis and Treatment Open access
José A. Inia, Geurt Stokman, Martine C. Morrison, Nicole Worms, Lars Verschuren, Martien P. M. Caspers, +7 more
27citations -
Oral semaglutide and CV benefits in the SOUL trial: how do baseline or changes in HbA1c and BMI affect clinical outcomes?2026 The Journal of Clinical Endocrinology & Metabolism article Medicine Diabetes Treatment and Management Open access
Silvio E. Inzucchi, Rohana Abdul Ghani, John Eric Deanfield, M D Engelmann, G. Kees Hovingh, Ole Kleist Jeppesen, +16 more
1citations -
Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis
Sharon L. Mulvagh, John E. Deanfield, Samuel Emerson, S E Inzucchi, Johannes F.E. Mann, Nikolaus Marx, +9 more
0citations -
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL , a randomized trial
Darren K. McGuire, Rodica Pop‐Busui, John Eric Deanfield, Silvio E. Inzucchi, Johannes F.E. Mann, Nikolaus Marx, +8 more
133citations -
Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide2023 European Heart Journal article Medicine Adipokines, Inflammation, and Metabolic Diseases Open access
Nikolaus Marx, John Eric Deanfield, Sofia Gerward, G. Kees Hovingh, O Plunde, Richard E. Pratley, +2 more
4citations -
Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis
Jorge Plutzky, Paweł Bogdański, Helen Martina Colhoun, Selçuk Dağdelen, John Eric Deanfield, Scott S. Emerson, +14 more
1citations -
PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease0citations